The primary outcome of the retrospective cohort study was postcolonoscopy colorectal cancer within three years, defined as colorectal cancer diagnosed within six and 36 months after negative findings on index colonoscopy.
Monotherapy for inflammatory bowel disease (IBD) with an immunosuppressive agent was associated with a lower risk of serious infection than a tumor necrosis factor (TNF) antagonist alone or an anti-TNF plus an immunosuppressive agent, according to a
An editorial said the results highlight the importance of alternative biologic treatments and regimens for some patients but noted that further research is needed on cost-effectiveness.
Highlights from the conference, held this past week in San Diego, included new research and clinical tips on stopping Barrett's esophagus surveillance, diet and environmental risk factors in patients with
A systematic review and network meta-analysis focused on alosetron, eluxadoline, ramosetron, and rifaximin in adult patients who had irritable bowel syndrome (IBS) with diarrhea or mixed stool.
Decompensation-free survival improved in patients with cirrhosis and portal hypertension who received beta-blockers versus placebo, largely due to a decrease in ascites.
There was no significant difference in upper GI events between a pantoprazole group and a placebo group, although pantoprazole was associated with significantly reduced bleeding of gastroduodenal lesions, an industry-funded study found.
The increase primarily occurred among people who reported drug use or homelessness.
Patients with ulcerative colitis treated with 5-aminosalicylates who require escalation to anti-tumor necrosis factor-alpha (anti-TNF) therapy may be able to safely discontinue the first drug.
The guideline focuses on oral and topical 5-aminosalicylic acid medications, rectal corticosteroids, and oral budesonide in patients with mild to moderate disease.